Avadel Pharmaceuticals plc(AVDL)2025-01-08 21:18Revenue and Financial Performance - LUMRYZ net revenue for Q4 2024 estimated at $50.0 million, a 150% increase compared to $19.5 million in Q4 2023[1] - Full-year 2024 net product revenue of approximately $169.0 million, up from $28.0 million in 2023[7] - 2025 net product revenue guidance for LUMRYZ is $240–$260 million, representing 50% year-over-year growth at the midpoint[1] - Cash, cash equivalents, and marketable securities totaled $73.0 million as of December 31, 2024[7] Patient Metrics and Therapy Adoption - 2,500 patients on LUMRYZ as of December 31, 2024, including 600 new patients initiating therapy in Q4[1] - 74% of patients on LUMRYZ therapy were reimbursed as of December 31, 2024[12] - 2025 guidance includes 2,800–3,000 new patient initiations and 3,300–3,500 total patients on therapy by December 31, 2025[12] Sales and Market Expansion - Expanded field sales team by nearly 15% to target under-penetrated prescribers[12] Research and Development - Phase 3 REVITALYZ study for idiopathic hypersomnia expected to complete in H2 2025[12] - Preclinical development ongoing for a low-/no-sodium oxybate formulation bioequivalent to LUMRYZ[12]